Epitope-specific monoclonal antibodies and immunotoxins and uses

Details Epitope-specific monoclonal antibodies and immunotoxins and uses Epitope-specific monoclonal antibodies and immunotoxins and uses

1994-02-22

1997-11-11

Scheiner, Toni R.

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

Conjugated to proteinaceous toxin or fragment thereof

5303917, 53038873, 435 724, A61K 39395

Patent

active

056860722

ABSTRACT:
The anti-tumor activity of a mixture of anti-CD22 and anti-CD19 immunotoxins is shown to be significantly enhanced in SCID/Daudi mice with disseminated human Daudi lymphoma. Unexpectedly identical enhancement was observed employing a combination of the anti-CD22 immunotoxin with unconjugated anti-CD19 antibodies. Thus combinations of an anti-CD22 immunotoxin and an anti-CD19 immunotoxin or antibody act synergistically and provide advantageous compositions and methods for immunotherapeutic treatment of various diseases including cancer and autoimmune disorders. Also disclosed is data indicating that certain anti-CD19 antibodies alone inhibit proliferation of CD19-positive cells by inducing cell cycle arrest.

REFERENCES:
patent: 4664911 (1987-05-01), Uhr et al.
patent: 4689311 (1987-08-01), Weltman
patent: 4831117 (1989-05-01), Uckun
patent: 4925922 (1990-05-01), Byers et al.
patent: 5045451 (1991-09-01), Uhr et al.
Canevari et al., Ann Oncol., vol. 5/8, pp. 698-701 1994.
Seaver, Gentic Engineering News, pp. 10 and 21, (1994).
Hermentin et al., Behring Inst. Mitt, No. 82, pp. 197-215 1988.
Rigley et al., Eur. J. Immunol., vol. 21, pp. 535-540, (1991).
Campana, D. et al., "Human B Cell Development I. Phenotypic Differences of B Lymphocytes in the Bone Marrow and Peripheral Lymphoid Tissue," The Journal of Immunology, 134(3):1524-1530, 1985.
Fulton, R. J. et al., "In Vivo Therapy of the BCL Tumor: Effect of Immunotoxin Valency and Deglycosylation of the Ricin A Chain," Cancer Research, 48:2626-2631, 1988.
Ghetie, M. et al., "Antitumor Activity of Fab' and IgG-anti-CD22 Immunotoxins in Disseminated Human B Lymphoma Grown in Mice with Severe Combined Immunodeficiency Disease: Effect on Tumor Cells in Extranodal Sites," Cancer Research, 51:5876-5880, 1991.
Ghetie, M. et al., "Evaluation of Ricin A Chain-containing Immunotoxins DIrected against CD19 and CD22 Antigens on Normal and Malignant Human B-Cells as Potential Reagents for in Vivo Therapy," Cancer Research, 48:2610-2617, 1988.
Ghetie, V. et al., "Large Scale Preparation of Immunotoxins Constructed with the Fab' Fragment of IgG1 Murine Monoclonal Antibodies and Chemically Deglycosylated Ricin A Chain," Journal of Immunological Methods, 112:267-277, 1988.
Katz, F. E. et al., "Elimination of T Cells From Human Peripheral Blood and Bone Marrow Using A Cocktail of Three Anti-T Cell Immunotoxins," British Journal of Haematology, 67:407-411, 1987.
Li, J. et al., "The Epitope Specificity and Tissue Reactivity of Four Murine Monoclonal Anti-CD22 Antibodies," Cellular Immunology, 118:85-99, 1989.
May, R.D. et al., "Selective Killing of Normal and Neoplastic Human B Cells with Anti-CD19-and Anti-CD22-Ricin A Chain Immunotoxins," Cancer Drug Delivery, 3(4):261-272, 1986.
Kiesel, S. et al., "Functional Evaluation of CD19-and CD22-Negative Variants of B-Lymphoid Cell Lines," Immunology, 64:445-450, 1988.
Raso, Vic, an Griffin, Thomas, "Specific Cytotoxicity of a Human Immunoglobulin-Directed Fab'-Ricin A Chain Conjugate," The Journal of Immunology, 125(6):2610-2616, 1980.
Shen, G. et al., "Evaluation of Four CD22 Antibodies As Ricin A Chain-Containing Immunotoxins for The In Vivo Therapy of Human B-Cell Leukemias and Lymphomas," International Journal of Cancer,42:792-797, 1988.
Thorpe, P.E. et al., "Modification of the Carbohydrate in Ricin with Metaperiodate--Cyanoborohydride Mixtures," European Journal of Biochemistry, 147:197-206, 1985.
Till, M. et al., "An Assay That Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-Containing Immunotoxins," Cancer Research, 48:1119-1123, 1988.
Vitetta, E.S. et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents," Science, 238:1098-1104, 1987.
Vitetta, E.S. et al., "Phase I Immunotoxin Trial in Patients with B-Cell Lymphoma," Cancer Research, 51:4052-4058, 1991.
Borrebaeck, "Strategy for the production of human monoclonal antibodies using in vitro activated B cells," Journal of Immunological Methods, 123:157-165, 1989.
Dorken et al., "HD39 (B3), A B Lineage-Restricted Antigen Whose Cell Surface Expression is Limited to Resting and Activated Human B Lymphocytes," The Journal of Immunology, 136(12):4470-4479, 1986.
Ghetie et al., "The Antitumor Activity of an Anti-CD22 Immunotoxin in SCID Mice With Disseminated Daudi Lymphoma Is Enhanced by Either an Anti-CD19 Antibody or an Anti-CD19 Immunotoxin," Blood, 80(9):2315-2320, 1992.
Goding, "Antibody Production by Hybridomas," Journal of Immunological Methods, 39:285-308, 1980.
Jansen et al., "Establishment of a Human t(4;11) Leukemia in Severe Combined Immunodeficient Mice and Successful Treatment Using Anti-CD19 (B43)-Pokeweed Antiviral Protein Immunotoxin," Cancer Research, 52:406-412, 1992.
Mason et al., "Value of Monoclonal Anti-CD22 (p135) Antibodies for the Detection of Normal and Neoplastic B Lymphoid Cells," Blood, 69(3):836-840, 1987.
Moldenhauer et al., "Characterization of a Human B Lymphocyte-Specific Antigen Defined by Monoclonal Antibodies HD6 and HD39," Leukocyte Typing II, vol. 2, Chapter 7, pp. 97-107. (1986).
Osband and Ross, "Problems in the investigational study and clinical use of cancer immunotherapy," Immunology Today, 11(6):193-195, 1990.
Vuist et al., "Poentiation by Interleukin 2 of Burkitt's Lymphoma Therapy with Anti-Pan B (Anti-CD19) Monoclonal Antibodies in a Mouse Xenotransplantation Model," Cancer Research, 49:3783-3788, 1989.

Affiliated with

Also associated with

Rating

Epitope-specific monoclonal antibodies and immunotoxins and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Epitope-specific monoclonal antibodies and immunotoxins and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epitope-specific monoclonal antibodies and immunotoxins and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1226562